At the #STATSummit, Daniel Jernigan recounts what it was like at the CDC after a gunman had opened fire on the building.

STAT's @matthewherper.bsky.social asks Eli Lily's Daniel Skovronsky about hiring Peter Marks and the revolving door of talent at the FDA.
#STATSummit

The US is currently a biotech leader, but the inconsistency at the FDA will make it hard to make new medicines.

“I think this is going to kill drug development,” Replimune CEO Sushil Patel told Adam Feuerstein at the #STATSummit.

The U.S. pharmaceutical industry is at a “Sputnik moment,” says Alnylam Pharmaceuticals founder John Maraganore.

“We need to think about the cost of our research and development activities and how to do it cheaper. We have to be competitive with what China is doing.”
#STATSummit

President Trump’s bid to lower drug prices for Americans, his most favored nation policy, “is pretty catastrophic for the industry,” said Biogen head Chris Viehbacher.

“We can’t just unwind years of how we’ve had to deal with governments.”
#STATSummit

Stephen M. Taylor, president of the American Society of Addiction Medicine, talks with STAT’s addiction reporter Lev Facher about medications for opioid use disorder vs. 12-step programs.
#STATSummit

Kyle Muldoon thought he might never get to watch an Eagles game with his son KJ, who was born with a rare and fatal liver disease that was treated with an individual CRISPR therapy.
#STATSummit

The technology that saved baby KJ was built over decades of basic science. Kiran Musunuru, a researcher at the University of Pennsylvania, breaks down everything that was needed to make sure KJ’s doctors could put together a treatment on demand. #STATSummit

At #STATSummit, @joekennedyiii.bsky.social talks about the impact of community health centers.

"At one point, we sent doctors to communities to treat people. Now, we're sending the National Guard. Why?"

Modifying Medicaid systems for a new task like implementing Medicaid work requirements is difficult.

“To call our IT systems dinosaurs would be charitable,” said Mike Levine, undersecretary at Massachusetts’ Medicaid organization MassHealth.
#STATSummit

Noubar Afeyan founded Flagship Pioneering, best known for its company Moderna, which commercialized mRNA vaccines.

Onstage at the #STATSummit, he lays out why the attack on mRNA undermines facts and science and isn’t going to stop at mRNA.

Alondra Nelson Former Director White House Office of Science and Technology Policy, talked about how her military family and background always instilled the duty to serve — no matter the political party. Then she explained why she ultimately ended up having to leave.
#STATSummit

At the #STATSummit, former NIH National Human Genome Research Institute director Eric Green talks to STAT’s @aniloza.bsky.social about the cuts at the NIH.

“There’s no reason to think we’ve bottomed out,” he said. “We can’t rebuild until we know what we even have left.”

STAT's @matthewherper.bsky.social asks Eli Lily's Daniel Skovronsky about hiring Peter Marks and the revolving door of talent at the FDA.
#STATSummit

A #STATSummit attendee asks: Are there risks to the AMA not being more vocal?

AMA president Bobby Mukkamala says the org can be more vocal with patients, but it doesn't want to be critical. AMA is excited about the administration's efforts to help doctors, he says:

Capricor CEO Linda Marbán talks with Adam Feuerstein about Peter Marks and the new FDA.

“The fact, Adam, that you even just had to allude to pissing somebody off in order to potentially impact the approval of your drug is a little scary, right? It should be based on the data.”
#STATSummit